Antidepressants Drugs
Publication Date
February 2024
USD 20.71 billion
USD 39.99 billion
USD 22.44 billion
Antidepressants Drugs Market by Drug Class (Monoamine Oxidase Inhibitors, Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors), Indication (Anxiety Disorders, Attention Deficit Hyperactivity Disorder, Major Depressive Disorder), Route of Administration, Distribution Channel - Global Forecast 2024-2030

[182 Pages Report] The Antidepressants Drugs Market size was estimated at USD 20.71 billion in 2023 and expected to reach USD 22.44 billion in 2024, at a CAGR 9.85% to reach USD 39.99 billion by 2030.

Antidepressants Drugs Market
To learn more about this report, request a free sample copy

Antidepressants are a medication used to treat major depression, anxiety disorders, chronic pain, and addiction. The primary goal of antidepressant treatments is to alleviate the symptoms of severe depression, such as feeling down and exhausted, and to keep them from recurring. The rising prevalence of post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and anxiety issues have increased the need for antidepressant medications. Furthermore, rising public awareness of mental health issues and favorable government support has increased the use of antidepressant medications. However, negative health issues, expensive treatments, and the stigma associated with mental health problems may inhibit market growth. However, ongoing product development and surging regulatory approvals may create enormous market opportunities.

Antidepressants Drugs Market - Global Forecast 2024-2030
To learn more about this report, request a free sample copy
Regional Insights

From a geographical perspective, the American region is considered the prominent user of antidepressant drugs due to the high demand for disease-specific treatment, the rise in adoption of newer technologies, the presence of refined healthcare expenditure, increased patient awareness, and the high prevalence of depression. Moreover, the growing approvals from the Food and Drug Administration (FDA) and ongoing research and development (R&D) activities in the United States have facilitated the adoption of antidepressants to counter depression, anxiety disorders, and other mental disease. Additionally, the increased prevalence of common mental disorders, antidepressant prescription over non-pharmacological therapies, growing access to antidepressants, or low investment in therapeutic innovation in European countries have enlarged the market growth. At the same time, favorable government initiatives and campaigns and rising public awareness about mental health in the Asia-Pacific region have initiated the adoption of antidepressants. Asia-Pacific is believed to have lucrative growth due to the presence of globally marketed players in this region and growing cases of mental illness.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antidepressants Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antidepressants Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Alembic Pharma gets USFDA nod to market generic antidepressant drug

    Alembic Pharmaceuticals, a leading pharmaceutical provider in India, recently received US Food and Drug Administration (USFDA) approval to market a generic antidepressant drug. This revolutionary new medication is an important milestone in the pharmaceutical industry and will bring many benefits to those living with depression. The availability of this generic antidepressants drug presents one more potential path for improving mental health that may lead to greater access and affordability. Not only will it be more affordable than other leading medications, but the medication is expected to have fewer side effects as well. With USFDA approved generic antidepressant drugs becoming increasingly common, now might be the perfect time for those suffering from symptoms of depression to explore this new avenue for treatment. [Published On: 2023-03-09]

  • Acquisition of CinCor Pharma complete

    AstraZeneca is pleased to announce the acquisition of Cincor, a cardiovascular and renal therapeutics treatments company. This strategic move enables AstraZeneca to expand its portfolio into the depression drug market, allowing them to better meet the needs of their customers worldwide. With more than two decades of research and development experience, Cincor brings with them a wealth of knowledge in this field that bolsters AstraZeneca's efforts to produce safe, reliable treatments for those suffering from depression. As a global leader in healthcare applications, this acquisition further strengthens AstraZeneca's ability to provide reliable solutions for customers around the world. We are confident that together, our teams will successfully leverage this asset to produce innovative treatments that improve patient outcomes and enhance the quality of life for those suffering from challenging mental health conditions. [Published On: 2023-02-24]

  • Zydus gets USFDA nod to market generic medicine for treating depression

    The Antidepressants Drugs market is booming, with Zydus recently receiving the go-ahead from the USFDA to market its generic version of a medicine used in the treatment of depression. This news follows hot on the heels of Granules India's announcement that it too has received U.S. FDA nod to manufacture and market an antidepressant product, potentially bridging major gaps in healthcare access across India's population. With more companies investing in this sector, efforts have been intensified to make effective and affordable treatment options available for those suffering from mental health issues. It is clear that this industry is starting to take a greater role in providing solutions for those needing antipsychotic medications, setting the stage for success and wide-reaching support throughout society. [Published On: 2023-01-16]

Key Company Profiles

The report delves into recent significant developments in the Antidepressants Drugs Market, highlighting leading vendors and their innovative profiles. These include A. N. Pharmacia Laboratories Pvt. Ltd., AbbVie Inc., Alkermes PLC, Angelini Pharma S.p.a., Apotex Inc., AstraZeneca PLC, Biogen Inc., Bristol Myers Squibb Company, CAPLYTA by Intra-Cellular Therapies, Inc., Divi’s Laboratories Limited, Dr. Reddy’s Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, Eridanus Healthcare, H. Lundbeck A/S, Jabs Biotech Pvt. Ltd., Johnson & Johnson Services, Inc., La Renon Healthcare Pvt. Ltd., Lupin Ltd., Mallinckrodt PLC, Merck & Co., Inc., Midas Pharma GmbH, Neurocon Inc., Organon & Co., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH by Novartis AG, Sanofi S.A., Somacare, SteriMax Inc., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A., and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Antidepressants Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Monoamine Oxidase Inhibitors
    • Reuptake Inhibitors
    • Selective Serotonin Reuptake Inhibitors
    • Serotonin Antagonist
    • Serotonin-Norepinephrine Reuptake Inhibitors
    • Tricyclic Antidepressants
  • Indication
    • Anxiety Disorders
    • Attention Deficit Hyperactivity Disorder
    • Major Depressive Disorder
  • Route of Administration
    • Injectable
    • Oral
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Antidepressants Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antidepressants Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Antidepressants Drugs Market?
  4. What is the market share of the leading vendors in the Antidepressants Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Antidepressants Drugs Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Antidepressants Drugs Market, by Drug Class
  7. Antidepressants Drugs Market, by Indication
  8. Antidepressants Drugs Market, by Route of Administration
  9. Antidepressants Drugs Market, by Distribution Channel
  10. Americas Antidepressants Drugs Market
  11. Asia-Pacific Antidepressants Drugs Market
  12. Europe, Middle East & Africa Antidepressants Drugs Market
  13. Competitive Landscape
  14. Competitive Portfolio
Companies Mentioned
  • A. N. Pharmacia Laboratories Pvt. Ltd.
  • AbbVie Inc.
  • Alkermes PLC
  • Angelini Pharma S.p.a.
  • Apotex Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol Myers Squibb Company
  • CAPLYTA by Intra-Cellular Therapies, Inc.
  • Divi’s Laboratories Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Eridanus Healthcare
  • H. Lundbeck A/S
  • Jabs Biotech Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • La Renon Healthcare Pvt. Ltd.
  • Lupin Ltd.
  • Mallinckrodt PLC
  • Merck & Co., Inc.
  • Midas Pharma GmbH
  • Neurocon Inc.
  • Organon & Co.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH by Novartis AG
  • Sanofi S.A.
  • Somacare
  • SteriMax Inc.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Wellona Pharma
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Antidepressants Drugs Market
The Global Antidepressants Drugs Market size was estimated at USD 20.71 billion in 2023 and expected to reach USD 22.44 billion in 2024.
The Global Antidepressants Drugs Market to grow USD 39.99 billion by 2030, at a CAGR of 9.85%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.